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Abstract
Rationale: Synaptic dopamine (DA) release induced by amphetamine or other
experimental manipulations can displace [11C]raclopride (RAC*) from
dopamine D2-like receptors. We hypothesized that exogenous levodopa might
increase dopamine release at striatal synapses under some conditions but not
others, allowing a more naturalistic assessment of presynaptic dopaminergic
function. Presynaptic dopaminergic abnormalities have been reported in
Tourette syndrome (TS).
Objective: Test whether levodopa induces measurable synaptic DA release in
healthy people at rest, and gather pilot data in TS.
Methods: This double-blind crossover study used RAC* and positron emission
tomography (PET) to measure synaptic dopamine release 4 times in each of 10
carbidopa-pretreated, neuroleptic-naïve adults: before and during an infusion of
levodopa on one day and placebo on another (in random order). Five subjects
had TS and 5 were matched controls. RAC* binding potential (BPND) was
quantified in predefined anatomical volumes of interest (VOIs). A separate
analysis compared BPND voxel by voxel over the entire brain.
Results: DA release declined between the first and second scan of each day
(p=0.012), including on the placebo day. Levodopa did not significantly reduce
striatal RAC* binding and striatal binding did not differ significantly between TS
and control groups. However, levodopa’s effect on DA release differed
significantly in a right midbrain region (p=0.002, corrected), where levodopa
displaced RAC* by 59% in control subjects but increased BPND by 74% in TS
subjects.
Discussion: Decreased DA release on the second scan of the day is
consistent with the few previous studies with a similar design, and may indicate
habituation to study procedures. We hypothesize that mesostriatal DA neurons
fire relatively little while subjects rest, possibly explaining the non-significant
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effect of levodopa on striatal RAC* binding. The modest sample size argues for
caution in interpreting the group difference in midbrain DA release with
levodopa.
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Introduction
Dopamine (DA) release from neurons has often been conceptualized as occurring via two separable mechanisms: tonic, referring
to low levels of DA in extrasynaptic spaces that may be more
accessible to microdialysis, and phasic, referring to synaptic DA
release at synapses following presynaptic action potentials1. Phasic dopamine release is crucial to dopamine’s role in changing
behavior2, including in learning sequences of movements3. Normal
tonic dopamine release but abnormal phasic dopamine release has
been postulated to occur in several disease states, including drug
abuse4 and Tourette syndrome (TS)5–8.
The radioligand [11C]raclopride (hereinafter RAC*) binds to
dopamine D2-like (D2, D3 and D4) receptors loosely enough to be
displaced by physiological increases of dopamine at the synapse.
This property has been exploited to detect changes in synaptic
DA release induced by experimental manipulations including the
administration of amphetamine9. However, amphetamine also has
some disadvantages in this context—primarily, that it does not really
produce phasic dopamine release in the usual, temporal, sense of
the word. Rather, it causes prolonged, substantial dopamine release
regardless of environmental demands. Scientific questions about
DA release in the absence of amphetamine might be better tested
with a pharmacological stimulus that could potentially increase
the magnitude of DA release, but under tighter endogenous control. Additionally, amphetamine can induce symptomatic effects
including euphoria10 and transiently increased tic severity11; these
effects can themselves alter brain activity, complicating interpretation of the results. Ideally, a pharmacological challenge drug to
test phasic dopamine release would not produce effects noticed by
the subject.
The present study provides preliminary data for a novel approach
to testing presynaptic dopamine release using levodopa, the body’s
natural synthetic precursor to dopamine. Exogenous levodopa
boosts dopamine synthesis almost immediately in both parkinsonian and healthy brains [reviewed in 12]. The extra dopamine is rapidly released at the synapse in people with DA deficiency13, and
there is evidence that this happens also in the non-parkinsonian
brain. In people, including in people with tics, levodopa produces
dose-dependent yawning, mild sleepiness, and effects on working
memory—i.e., CNS-mediated effects14–16. Additional evidence for
levodopa-induced synaptic DA release in the non-parkinsonian
brain is reviewed in 12. When given after an adequate dose of carbidopa, which prevents conversion to dopamine but does not cross the
blood-brain barrier, systemic levodopa administration essentially
delivers dopamine selectively to the brain, as confirmed by the
fact that it does not alter quantitative whole-brain blood flow17–19,
as dopamine would if it were being delivered systemically or produced outside the brain. In fact, with adequate carbidopa pretreatment, volunteers usually cannot tell whether they are receiving
levodopa or a placebo12,16.
We used PET and RAC* to measure synaptic dopamine release
in response to a standardized levodopa infusion (after carbidopa)
in 10 subjects. Since no previous data were available on levodopa
effects on RAC* PET, we included before- and during-levodopa
RAC* PET scans as well as before- and during-placebo scans. Half

of the subjects had a chronic tic disorder and the other half were
matched control subjects without tics, to generate preliminary data
in each population. The original hypotheses were that levodopa
would stimulate striatal dopamine production in the controls, but
may affect people with TS differently.

Methods
Participants
This study was approved by the Human Studies Committee of
Washington University School of Medicine (IRB, protocol # 03-0347,
the WUSM Radioactive Drug Research Committee (protocol #
497F), and the U.S. Food and Drug Administration (Investigator
IND #69,745 for i.v. levodopa). All subjects provided written confirmation of informed consent before study participation.
Diagnostic assessment included psychiatric and neurological examination by a movement-disorders-trained neuropsychiatrist (KJB)
and a validated semistandardized psychiatric diagnostic interview
[SCID-IV; 20]. Tic subjects met DSM-IV-TR criteria for Tourette’s
Disorder. Control subjects with no history of tics were matched
one-to-one for age, sex and handedness (with one ambidextrous
TS subject matched to a right-handed control). Exclusion criteria
included any lifetime neurological or Axis I psychiatric disorder
(except that TS, ADHD and OCD were allowed in tic subjects, and
migraine and specific phobia were allowed in either group), current
serious general medical illness, medication history of dopamine
antagonists or other drugs likely to affect the dopaminergic system,
current use of any neuroactive medication, lactation, possibility of
pregnancy, or contraindication to levodopa or MRI.
Clinical features were characterized by the Diagnostic Confidence
Index (0=no features of TS; 100=all enumerated features of classic
TS; scores in the original clinical validation sample ranged from 5
to 100, mean=61, S.D.=20)21; the YGTSS, an expert-rated measure
of tic severity over the previous week (motor tic scale 0–25, vocal
tic scale 0–25, impairment scale 0–50, higher scores indicating a
higher symptom burden)22,23; the revised Tic Symptom Self-Report
(TSSR) scale, a self-report scale including scores of 0–3 for each
of 18 motor tics and 16 vocal tics, with 3 indicating tics were “very
frequent and very forceful” over the preceding two weeks24,25; the
ADHD Rating Scale, an expert-rated measure of current severity of
Attention-Deficit/Hyperactivity Disorder (ADHD) based on DSMIV criteria (range 0–54, higher scores indicating a higher symptom burden)26; and the Y BOCS, an expert-rated measure of current
obsessive-compulsive disorder (OCD) severity (range 0–40, higher
scores indicating a higher symptom burden)27,28.

Overview of subject participation
Each subject had 4 RAC* PET scans: two scans on each of two days
at least a week apart (Figure 1). After oral carbidopa and the baseline PET scan, an infusion of levodopa or saline placebo was begun
by vein at an individualized dose intended to produce a steadystate levodopa plasma concentration of 600ng/mL. After allowing
30 minutes to approach steady-state levodopa concentration, a second scan was done while the infusion continued. The order (levodopa on day 1 and placebo on day 2, or the reverse) was assigned
randomly to each subject, and subjects and PET staff were blind to
drug assignment during all scans.
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The room was darkened and subjects were instructed to lie quietly
in the scanner with eyes closed throughout each scan. Study staff
asked subjects every 5 or 10 minutes if they were comfortable and
made sure they were awake.

radiotracer in the head and continuing for 60 minutes using image
frames of increasing duration. An MP-RAGE sequence was used
to acquire a 3-dimensional T1-weighted image of the brain with
acquisition time ~400 sec and voxel dimensions 1.25×1×1mm3.

Levodopa infusion
Subjects took 200mg carbidopa by mouth at least 1 hour before levodopa infusion began. A dose of levodopa estimated to fill each subject’s volume of distribution at a target concentration of 600ng/mL
was infused over 10 minutes, followed until the second PET scan
of the day was completed by a maintenance infusion at a rate estimated to compensate for elimination. In prior work, these infusion
rates produced a mean blood level across subjects of ~625ng/mL
after 25 minutes of infusion16. On average, that concentration produces substantial motor benefit in early Parkinson disease29,30, yet
this infusion method is well enough tolerated that subjects cannot
reliably distinguish the levodopa and saline infusions12,16.

Image alignment
The PET images were realigned within each subject and then to
the subject’s MRI using a rigid-body alignment method with low
measured error, optimized for dynamic PET images34–37.

Levodopa plasma concentration
Levodopa plasma concentration was measured by a validated
method31.
Radiotracer preparation
[11C]raclopride was prepared by O-[11C]methylation of (S)-Odesmethylraclopride HBr (ABX Advanced Biochemical Compounds, Radeberg, Germany) using a modification of previously
reported procedures32,33. Carbon-11 was produced as 11CO2 using the
Washington University JSW BC 16/8 cyclotron and the 14N(p,α)11C
nuclear reaction. The 11CO2 was converted to 11CH3I using the microprocessor-controlled PETtrace MeI MicroLab (GE Medical
Systems, Milwaukee, WI), and immediately used for [11C]methylation
of (S)-O-desmethylraclopride. Product [11C]raclopride was purified via semipreparative HPLC, and reformulated in a 10% ethanol/
normal saline solution. The radiochemical purity exceeded 95%,
and the specific activity exceeded 500 Ci/mmol, as determined
by analytical HPLC. The mass of raclopride was ≤13.9 µg per
injected dose.

VOI analysis
Nine subcortical volumes of interest (VOIs) were defined for
each subject from that subject’s MRI by a high-dimensional semiautomated method of known high test-retest reliability38 (Figure 2).
These VOIs corresponded to the thalamus and the left and right
putamen, caudate, nucleus accumbens, and globus pallidus. An
additional VOI was created from the average (weighted by region
volume) of 22 FreeSurfer-labeled gray matter regions comprising
frontal cortex (11 left- and 11 right-hemisphere VOIs). This large
frontal VOI produced adequate counting statistics for modest noise
in the time-activity curve (Figure 3). A cerebellum VOI was traced
on each subject’s MR image. All VOIs were transferred to each
subject’s realigned PET images using the optimized MRI-to-PET
transformation matrix computed in the alignment step. The cerebellar VOI was trimmed if needed so that no voxel in the VOI corresponded to any of the inferior-most four slices in any frame of that
subject’s original PET images. Thus in each subject each VOI was
identical for all four PET scans.
The binding potential BPND39,40, an estimate of the quotient Bmax/KD,
was computed as one less than the distribution volume ratio (DVR),
which was derived for each of the nine subcortical VOIs and the
frontal lobe VOI using the cerebellar reference region41. As we had
no a priori hypothesis about laterality of results in any of the paired
basal ganglia nuclei, we averaged corresponding left and right
BPNDs (weighted by VOI volume) to produce for each PET scan six

Image acquisition
RAC* was given i.v. over an interval of 30 seconds (median dose
14.8mCi, interquartile range 11.0–18.9mCi). PET images were
acquired on a Siemens ECAT 961 camera beginning with arrival of

PET
Day 1

raclo1

Day 2

raclo3

PET
saline
or levodopa
levodopa
or saline

raclo2
raclo4

Infusion rate:

Time
Figure 1. Study overview.

Figure 2. Automated striatal VOIs. Atlas-based VOI outlines are
shown on an axial section from one subject (Cd yellow, Pu light blue,
Pl white, Th red; NA does not appear on this section).
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Figure 3. Time-activity curves. Decay-corrected time-activity curves are shown for the right putamen (filled circles), the frontal lobe VOI (+’s),
and the cerebellar reference region (empty circles) from one subject’s pre-levodopa PET scan.

final BPND values, one each for frontal lobe cortex (FL), thalamus
(Th), putamen (Pu), caudate (Cd), nucleus accumbens (NA), and
globus pallidus (Pl).
The primary statistical analysis used a repeated-measures analysis
of variance (rmANOVA) with BPND as dependent variable, diagnosis (tic or control) as a between-group variable, time (before or
during the infusion) and day (placebo or levodopa) as withinsubject variables, and region (the six VOI-based BPNDs) as a repeated
measure. Exploratory analyses used an ANOVA for each region.

Whole-brain analysis
For each subject, a DVR image was computed using at each voxel
in the brain the Logan graphical method with the cerebellar VOI
described in the preceding section as reference region41. As a methods check, the mean across striatal VOIs of the voxelwise DVR
value was essentially identical to the regional DVR computed using
the standard methods described above. Analysis was limited to voxels in atlas space at which every subject contributed data from all
frames of the dynamic PET acquisition.
Whole-brain comparisons used voxelwise t tests corrected for multiple comparisons in SPM 8, as follows. A t test compared DVR
images between the TS and the control group, and clusters of contiguous voxels with t exceeding the threshold corresponding to
p<0.001 were accepted as significantly different between groups
if cluster volume exceeded the threshold required to control False
Discovery Rate (FDR) for the entire dataset at p<0.05.
Two comparisons were made, one based on mean baseline DVR
images and the other based on levodopa effect ΔDVR images. Each

subject’s two pre-infusion RAC* PET scans, one from each scan
day, were averaged to create that subject’s mean baseline DVR
image. The difference of the during-levodopa DVR image and the
during-placebo DVR image in a subject was used to create that subject’s levodopa effect ΔDVR image.

Results
Subjects
Subject characteristics and adequacy of matching are reported in
Table 1, and clinical characteristics of the TS group are reported
in Table 2.

Levodopa levels
Levodopa plasma concentrations were ~800–1000ng/ml before the
RAC* scan and ~500–700ng/ml after the RAC* scan, and did not
differ significantly between groups (Table 3).
Table 1. Subject characteristics and adequacy of matching.
Measure

Tic Subjects
(N=5)

Controls
(N=5)

Age (years; mean ± S.D.)

33.8 ± 12.9

32.8 ± 11.1

Sex, male (N)

4

4

Race, Caucasian (N)

4

4

Handedness, right (N)

4

3

OCD diagnosis (N)

1

0

ADHD diagnosis (N)

2

0

Abbreviations: OCD=Obsessive-compulsive disorder, ADHD=Attention
Deficit Hyperactivity Disorder.
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Counting statistics in VOIs at baseline
The a priori VOIs showed higher and more reliable binding in
striatum and pallidum, as expected. Nevertheless, the thalamus,
GP and frontal cortex VOIs also produced good counting statistics
(Figure 3). For every one of the VOIs the baseline BPND estimates
were positive in all 120 scans, and were very similar between the
two scan days (Table 4, Figure 4).

Table 2. Clinical characteristics of the Tourette syndrome
group. The Y BOCS was completed for only 1 tic subject; the
score was 9 on day 1 and 14 on day 2.

Table 3. Levodopa plasma concentrations in ng/ml, mean ± SD.
Time

Controls

Tic subjects

p (t test)

Peak (10' into
infusion)

1591.5 ± 232.5

1938.8 ± 726.3

0.36

Just before
RAC* scan

788.0 ± 152.4

992.4 ± 322.9

0.26

Just after
RAC* scan

529.5 ± 149.2

662.8 ± 136.1

0.21

Table 4. RAC* binding in a priori VOIs at baseline.
Scale

Scores
(mean ± S.D.)

VOI

FL

Th

Pl

NA

Cd

Pu

DCI score

36.8 ± 22.0

BPND (mean)

0.15

0.32

1.11

1.80

2.13

2.79

Motor tic score

10.6 ± 3.4

0.05

0.08

0.20

0.30

0.45

0.42

Vocal tic score

7.8 ± 4.0

BPND (standard
deviation)

Impairment score

9.4 ± 9.8

BPND values > 0
(of 20 scans)

20

20

20

20

20

20

Motor

9.3 ± 5.9

.0000

.0000

.0000

.0000

.0000

.0000

Vocal

3.2 ± 2.3

p for mean > 0
(one-sample t test)

Total

12.5 ± 7.9

Correlation r
between days,
across subjects

.70

.63

.88

.76

.94

.96

p for correlation
(8 df, 1 tail)

.012

.025

.0003

.005

.0000

.0000

YGTSS

TSSR score

ADHD Rating Scale

11.6 ± 10.7

Abbreviations: DCI=Tourette Syndrome Diagnostic Confidence
Index, YGTSS=Yale Global Tic Severity Scale, Y-BOCS=Yale-Brown
Obsessive Compulsive Scale, ADHD=Attention Deficit Hyperactivity
Disorder, TSSR=Tic Symptom Self Report.

Abbreviations: FL, frontal lobes; Th, thalamus; Pl, pallidum; NA, nucleus
accumbens; Cd, caudate; Pu, putamen.

4.0
putamen
caudate
nucleus accumbens
pallidum
thalamus
frontal lobe
identity

3.5

BPND before levodopa

3.0
2.5
2.0

0.5
0.4

1.5

0.3

1.0

0.2
0.1

0.5

0.0
0.0

0.0
0.0

0.5

1.0

1.5

2.0

2.5

0.1

3.0

0.2

0.3

3.5

0.4

0.5

4.0

BPND before placebo
Figure 4. Stability of baseline binding between scan days in the a priori VOIs. BPNDs from the first scan of each day are plotted for all 10
subjects, with the BPND from the pre-placebo scan on the horizontal axis and from the pre-levodopa scan on the vertical axis. For the paired
VOIs the mean of the left and right BPND is used. The diagonal line is the line of identity. The inset shows an enlarged view of the data from the
frontal lobe and thalamus VOIs.
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Stability of RAC* binding between days and with time
This study includes a before- and after-infusion scan on each of two
days. On one day the infusion contains levodopa, and on the other
day it is a saline placebo. Thus each subject has three non-levodopa
scans (the first scan of each day plus the scan during the placebo
infusion). As expected, BPND was quite reproducible in the two prelevodopa scans (correlated at r = 0.99 across VOI and subject).
To our surprise, BPND increased between the 1st and 2nd scan of
the day (main effect of time, F=10.605, df=1,8, p=0.012), and this
change did not differ significantly between the levodopa and placebo days (time × day interaction, F=0.014, df=5,4, p=0.909). In
other words, the two scans on the placebo day were not identical.
Mean BPND was 2.7% to 24.0% higher during the placebo infusion,
indicating decreased dopamine release compared to earlier on the
same day. The change from the first to the second scan of each day
was significant in most individual region analyses: main effect of
time, thalamus p=0.002, frontal lobe p=0.032, caudate p=0.039, pallidum p=0.048, and nucleus accumbens p=0.052 (multivariate time
× region interaction F=4.173, df=5,4, p=0.096). Figure 5 shows the
BPND for each VOI from both scans on the placebo day only.

Effect of levodopa on RAC* binding
Since the pre- and on-placebo scans differed, the appropriate comparison for the on-levodopa RAC* scan is the on-placebo scan.
Therefore we assessed the effect of levodopa by comparing the
BPND in the on-LD and on-placebo scans. In the VOI analysis, there
was no significant effect of LD (day × time interaction, F=0.014,
df=1,8, p=0.909).
Comparison of RAC* binding between TS and control groups
TS vs control at baseline. For the ANCOVA across all regions,
RAC* binding did not differ significantly between tic and control
subjects (main effect of diagnosis, F=0.744, df=1,8, p=0.413; tic
vs control). Nevertheless, baseline RAC* binding was numerically

higher in TS by 13–17% in the three striatal VOIs and by 5–7% in
the frontal lobe and thalamus VOIs. The whole-brain analysis identified no significant regional differences in baseline RAC* binding
between TS and control subjects.
TS vs control: time effect (change from first to second scan).
There was a trend for the change in BPND during the infusion to
be smaller in tic subjects (time × diagnosis interaction F=4.211,
df=1,8, p=0.074). Each of the three striatal regions showed a similar
effect when analyzed individually (0.05 < p < 0.10). Figure 6 shows
the VOI BPND values before and during the placebo infusion, by
diagnosis.
TS vs control: effect of levodopa on RAC* binding. In the a priori
VOIs, the effect of LD did not differ overall in tic subjects (day
× time × diagnosis interaction, F=1.308, df=1,8, p=0.286), and
the 4-way interaction (day × time × diagnosis × region) was not
significant (F=1.577, df=5,4, p=0.340). Although not statistically
significant, pallidal and thalamic BPND tended to decrease in control subjects but increase in the tic subjects (Figure 7).
The whole-brain analysis identified a similar but statistically significant effect in two clusters, where RAC* binding decreased
with levodopa in controls, consistent with increased dopamine
release during the levodopa infusion, but RAC* binding increased
in the TS group. The first cluster included 38 voxels in midbrain
(1.0 ml, FDR corrected p=0.002), with a peak t value of 9.0
(8 df) at atlas coordinate (1.5, −21, −15) and extending laterally
in approximately the right substantia nigra/ventral tegmental area
(Figure 8a). A second significant cluster of 19 voxels (0.5 ml, corrected p=0.023) occurred in parahippocampal gyrus, with peak
t=7.92 at (22.5, −39, −6) (Figure 8b). The mean change in BPND
with levodopa in these regions is shown in Figure 8c. In both these
clusters, the BPND on placebo was positive in all subjects (p < 0.001,
binomial distribution), consistent with nontrivial RAC* binding.

3.5
3.0

scan 1

scan 2

0.039

2.5

0.052
2.0

0.048

1.5
1.0
0.5

0.002
0.032

0.0
Frontal Lobe

Thalamus

Pallidum

Nucleus
Accumbens

Caudate

Putamen

Figure 5. Change in BPND on the placebo day. For each of the a priori VOIs, mean BPND across all 10 subjects is shown before and during
the infusion on the placebo day only. Error bars show SD. Numeric labels are p values for the main effect of time in the individual region
ANOVAs (putamen p=.115).
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3.5

0.089

control, scan 1
3.0

BPND

2.5

control, scan 2

0.094

tic, scan 1
tic, scan 2

0.071

2.0
1.5
1.0
0.5
0.0
Frontal Lobe

Thalamus

Pallidum

Nucleus
Accumbens

Caudate

Putamen

Figure 6. Change in [11C]raclopride binding on placebo day, by diagnosis. Mean BPNDs from the a priori VOIs, before and during the
infusion on the placebo day only. Error bars show SD. The p values shown are for the time × diagnosis interaction in the individual region
ANOVAs.

3.5

control, placebo
3.0

control, levodopa
tic, placebo

BPND

2.5

tic, levodopa

2.0
1.5
1.0
0.5
0.0
Frontal Lobe

Thalamus

Pallidum

Nucleus
Accumbens

Caudate

Putamen

Figure 7. Levodopa-induced change in BPND, by diagnosis. Mean BPND for the a priori VOIs is shown during the levodopa and placebo
infusions; the error bar indicates SD. The day × time × diagnosis interaction and the day × time × diagnosis × region interaction were not
significant. The daggers indicate a trend in the thalamic and pallidal VOIs for BPND to decrease with levodopa in the control group but
increase with levodopa in the tic group (regional ANOVA, day × time × diagnosis interaction, pallidum p=0.050, thalamus p=0.098).

The highest t value in the whole-brain comparison, 11.62, occurred
in Brodmann’s area 13, but the cluster volume was only 0.1 ml, not
significant by FDR correction (Figure 8d).

Discussion
Change in striatal BPND on the placebo day

BPND increased from before to during the placebo infusion in the
striatum, thalamus and frontal lobe VOIs, especially in control

subjects (Figure 5, Figure 6). Surprisingly little information
describes within-day stability of RAC* binding, though several
studies compare binding across time intervals of days to months42–45.
Mawlawi et al.46 scanned 10 subjects twice each on the same day
using a bolus-plus-constant-infusion method, and found no significant mean change from the first to the second scan. However,
Alakurtti and colleagues47 found that mean BPND increased from the
first to the second scan of the day in striatal and thalamic regions,
Page 8 of 17
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0.10

0.00

R. substantia nigra

PHG

Figure 8. RAC* binding on levodopa vs. placebo, by diagnosis. Differences in the RAC* binding response to levodopa between TS and
control subjects, thresholded at uncorrected p = 0.001, in color, laid over the MRI template image in grayscale. a, b: Significant clusters, with
blue lines crossing at the peak t value in midbrain (a, three views) and in parahippocampal gyrus (b). A third statistically significant cluster
was centered at the posterior edge of the occipital lobe, but both the location and the observation that in this cluster the BPND on placebo was
negative in half the subjects suggests that this cluster likely does not reflect specific binding. c: Levodopa-induced change in BPND, TS vs.
control, in the clusters shown in A and B. R., Right; PHG, parahippocampal gyrus. Asterisks indicate that mean BPND differs significantly from
zero. d: The blue lines cross at the voxel with the highest t value in the whole-brain SPM analysis of levodopa effect ΔDVR images (t=11.62, 8 df).

with the change (about +5%) reaching statistical significance in
medial and lateral thalamus.
The observation in the present study that BPND increased from the
first to second scan of the day is consistent with this background,
and is relevant to RAC* challenge PET studies in general, because
essentially all such studies use a before- vs. after-intervention
design. Slifstein et al. [48, p. 357] argue that the existence of placebo-induced DA responses make the before-after model more
appropriate for amphetamine challenge studies. However, our
results and those of Alakurtti et al.47 suggest that BPND increases

from the first to the second scan even without active intervention.
This does not invalidate the results of most before-after RAC* studies, since amphetamine challenge decreases striatal RAC* BPND by
a large fraction, and to a lesser extent so do many cognitive and
behavioral interventions in such studies, including studies of the
placebo effect. However, the present results suggest that beforeafter RAC* studies may be less sensitive to manipulations that
would decrease dopamine release.
Possible pathophysiological interpretation. The increase in BPND
during the placebo infusion is most likely associated with passage
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of time rather than a placebo effect per se, especially as placebo
administration is more likely to increase dopamine release48–50. The
presumed decrease in dopamine release during the placebo infusion
could indicate that control subjects accommodate to the scanner
environment over the course of the study day.

and in parahippocampal gyrus, levodopa stimulated dopamine
release in controls but reduced it in TS subjects in. A similar pattern, though not statistically significant, was observed in orbital
cortex (Brodmann’s area 13), thalamus and globus pallidus (Figure 7
and Figure 8d).

Effect of levodopa infusion on RAC* binding
Levodopa effect on RAC* binding in striatum. Striatal RAC* binding
was not substantially changed by levodopa. Initially this result came
as a surprise to the authors, because levodopa was given expressly
with the expectation that it would increase synaptic dopamine levels. Briefly, support for this expectation includes the following.
First, in Parkinson disease there is overwhelming evidence both by
clinical observations and by RAC* PET imaging that exogenous
levodopa substantially increases striatal dopamine release51–53. But
there is also evidence in subjects without dopamine deficiency:
intravenous levodopa is rapidly taken up from the bloodstream into
the brain and converted into dopamine, and several studies show
that it then boosts synaptic dopamine release [reviewed in 12]. For
instance, exogenous levodopa produces clear sedative and cognitive
effects in healthy people54–56. Thus the authors originally expected
that exogenous levodopa would decrease striatal RAC* binding.

One expects exogenous levodopa to increase dopamine release in
the substantia nigra, as occurred in the control subjects. D2 and D3
dopamine receptors are present in the substantia nigra and their
activation inhibits spike firing, dopamine synthesis and dopamine
release by nigral dopaminergic cells59. We hypothesize that levodopa increased dopamine stimulation of these inhibitory D2-like
receptors in control subjects, and this may have prevented levodopa from stimulating nigrostriatal dopamine release into the
striatum.

However, further reflection and reading have motivated a different view whereby the results support the original goal of choosing a pharmacological challenge agent that would stimulate phasic
dopamine release, but under endogenous control. Recall that the
concern with stimulants as challenge agents was that they cause a
substantial release of dopamine at the striatal synapse regardless
of current environmental demands; this approach may produce
a ceiling effect for dopamine release that does not reflect typical
endogenous control. A sensible hypothesis to explain the results of
the present study would be that a research subject lying awake in
a quiet, darkened room without specific cognitive demands has no
need for substantial phasic release of dopamine, and thus even if
exogenous levodopa has added dopamine to presynaptic vesicles,
they are not released at a substantial rate at the synapse. A levodoparaclopride study of a motor task in healthy individuals provides
direct experimental support of this hypothesis57. That study was
properly designed with two sessions, placebo on one day and levodopa on another, with randomized order. Levodopa increased striatal dopamine release during performance of a motor task, but not
at rest. Since in the present study all subjects were at rest during all
scans, the results are consistent with those of Flöel and colleagues57.

TS and control group comparisons
The tic and control subgroups have only five subjects each, and
differences between the tic and control groups in the a priori VOIs
were not statistically significant, so there is little need to comment
further on these results. Previous drafts of this report included such
discussion58.
The whole-brain analysis comparing RAC* binding with levodopa vs. placebo did identify statistically significant differences
(Figure 8a–c). In midbrain (approximately substantia nigra/VTA)

Subjects with TS, however, showed an increase in substantia nigra
RAC* binding with levodopa, consistent with a decrease in nigral
dopamine release. Nigral dopamine release has been related to
reward and novelty in humans. Healthy adults with higher novelty
seeking scores had lower D2-like binding ([18F]fallypride) in SN,
consistent with greater dopamine release60. Functional MRI studies
have also demonstrated substantia nigra signal related to stimulus
novelty or to the Novelty Seeking trait61–63. Healthy adults receiving
a sweet vs salty taste had BOLD activation in this region64. Despite
this information, it is not clear how to relate a decrease in levodopastimulated dopamine release in substantia nigra to the pathophysiology of TS. Explaining the similar difference in nigral levodopa
response in TS in parahippocampal gyrus and orbital cortex is no
easier, though dopaminergic effects on D2-like binding in hippocampus have been documented in Parkinson disease65 and dopamine
agonists evoke changes in orbital cortex activity66. The trend for
a similar effect in thalamus is consistent with a [11C]FLB-457
PET study in which amphetamine provoked thalamic dopamine
release in control subjects but not in TS67. Overall, these results
are consistent with an abnormality of presynaptic dopaminergic
pharmacology in TS, but the limitations of this comparison must
be acknowledged.

Limitations
Higher-affinity radioligands, such as [18F]fallypride or [11C]FLB
457, have advantages for measuring cortical D2Rs, e.g. in the frontal lobe where D2Rs appear at much lower concentrations than in
the striatum. There are two primary concerns with RAC* outside
the striatum [reviewed thoroughly in 9]. The first concern is a reliability issue: since the concentration of D2-like receptors is low
in cortex compared to striatum, the counting statistics are poor for
cortical VOIs of similar volume, and this renders the computed
BPNDs suspect. For instance, some regional RAC* BPNDs are negative or close enough to zero that displacement studies produce
results that are hard to interpret. In the present study, FreeSurferdefined cortical regions allowed the creation of a large, reliably
defined frontal lobe VOI, in which PET time-activity curves were
low in noise (Figure 3), allowing statistically reliable estimates of
BPND that were uniformly positive (Table 4, Figure 4). Similarly
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RAC* displacement in thalamus has shown adequate counting
statistics and reliability in previous studies47,68.
The second concern with RAC* in extrastriatal regions is one of
validity or interpretation. RAC* binding in cortex includes some
nonspecific binding33, so a fair question is to what extent specific
binding in cortex represents dopamine D2-like receptors. D2 and
D4 receptors are expressed in human prefrontal cortex, though at
relatively low concentrations compared to striatum69. On the other
hand, at least one study’s results suggest that raclopride may have
superior sensitivity to fallypride for measuring dopamine release in
some cortical regions70. The validity concern is less worrisome in
human thalamus, which contains predominantly D3 rather than D2
receptors71, and in substantia nigra, where D2 and D3 receptors are
well characterized. Other authors have interpreted substantia nigra
RAC* displacement as indicating synaptic dopamine release9.
Finally, comparing TS and control subgroups of only five subjects
each provides insufficient power to identify some true group differences (type II error). More importantly, the small sample size
lowers confidence in how representative the statistically significant
differences are of the overall population of adults with TS.

Future directions
These results suggest that a natural next step for research in TS is
to test whether dopamine release in TS differs during a dopaminereleasing cognitive (or other) task. Levodopa may augment the
task-evoked release or interact with it differently in people with
versus without tics. Along these lines, a cognitive-pharmacological
interaction fMRI study in TS found that LD changed the BOLD
responses to a working memory task72. A newer levodopa infusion
method produced roughly twice as high a levodopa plasma concentration as the infusion used in this study12, and may produce greater
dopamine release.
Dataset 1. PET images and clinical data
http://dx.doi.org/10.5256/f1000research.5672.d42172
The spreadsheet in OpenDocument file format provides the clinical
data and links each PET scan to the subject scanned and the
condition (i.e., before or during the placebo or levodopa infusion).
Also 40 PET files are provided with the filename extension .v, one
for each dynamic PET scan. These files are in ECAT file format;
users of other imaging file formats will find useful information at
the following web site: http://www.turkupetcentre.net/petanalysis/
format_image_ecat.html

Data availability
F1000Research: Dataset 1. PET images and clinical data, 10.5256/
f1000research.5672.d4217274
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Lars Nyberg
Umeå Center for Functional Brain Imaging, Umeå, Sweden
The most novel aspect of the study was the investigation of levodopa. This is very interesting. No
significant levodopa effects were, however, observed. The authors offer some interesting thoughts on the
reason for this null effect, most critically pointing to a need to have an active task PET design. This is a
plausible argument that may stimulate further research on this topic.
A potentially interesting methodological contribution is the observation of a difference between the 1st and
2nd scan on each day of scanning.
The study is likely underpowered, in particular for any group comparison (5 TS, 5 ctrls), so the
repeated-measures analysis was most likely not very sensitive. I would treat the observed differences
between TS and control groups from the whole-brain analysis as preliminary.
I may have missed it, but I could not find information about how the PET scans were reconstructed.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Competing Interests: No competing interests were disclosed.
Author Response ( F1000Research Advisory Board Member ) 24 Mar 2015

Kevin J Black, Department of Psychiatry, Washington University in St. Louis, USA
The authors thank Prof. Nyberg for the thoughtful review.
The [11C]raclopride PET data were collected in 3D mode and reconstructed on the Siemens ECAT
961 scanner console using filtered backprojection (ramp filter), with attenuation measured before
each emission scan using an external 68Ge/68Ga source.
We agree with all the reviewers that the between-group comparison is useful primarily as pilot data
because of the small group sizes.
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W.R. Wayne Martin
Division of Neurology, University of Alberta, Edmonton, AB, Canada
This is a carefully performed study that presents a novel approach to measure presynaptic dopamine
release using the administration of exogenous levodopa, coupled with raclopride PET scanning.
Preliminary data are provided using this method in a small group of controls and subjects with Tourette
syndrome.
The authors describe a decline in dopamine release in striatum, thalamus and frontal lobe between the
first and second scan of each day in response to placebo administration in normal subjects, possibly due
to habituation to study procedures. Levodopa administration did not alter striatal dopamine release
differently in Tourette syndrome vs. controls. However, dopamine release differed significantly in the
midbrain and parahippocampal gyrus in the two conditions. Levodopa stimulated dopamine release in
controls but reduced it in Tourette subjects.
Although these are important observations, the number of subjects studied was small. Hence, these must
be considered pilot data although they are consistent with a rather complex dopaminergic role in Tourette
syndrome. Of interest for future studies would be the evaluation of task-evoked dopamine release in
response to cognitive tasks. Lastly, the observation that habituation occurs in response to placebo
infusions has important implications to the interpretation of placebo-controlled studies of dopamine
release.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Competing Interests: No competing interests were disclosed.
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Marie Vidailhet
Department of Research of Technology and Development, Hôpital Pitié Salpêtrière, Paris, France
The authors studies the raclopride binding (displacement) in groups of subjects (normal and Tourette
syndrome). They studied the effect of levodopa infusions and of a placebo. The subjects were studied at
rest.
Basically, they found that in Tourette syndrome, dopamine release was smaller (reduced) than in
controls, in midbrain (approximately substantia nigra/VTA) and in parahippocampal gyrus.
This is an interesting paper and the methodology is adequate. The subjects are studied at rest, this may
underestimate the dynamic of dopamine release and it would have be more interesting to study this
phenomenon during a task. The groups are very small, and the effect in Tourette syndrome may also be
different according to the characteristics of the patient (with or without additional behavioral disorders).
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phenomenon during a task. The groups are very small, and the effect in Tourette syndrome may also be
different according to the characteristics of the patient (with or without additional behavioral disorders).
Nevetherless, the study is consistent with the presence of abnormality of presynaptic dopaminergic
pharmacology in Tourette syndrome.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Competing Interests: No competing interests were disclosed.
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Version 1

Author Response ( F1000Research Advisory Board Member ) 06 Jul 2015

Kevin J Black, Department of Psychiatry, Washington University in St. Louis, USA
In reviewing structural MR studies of TS, I noticed that Garraux and colleagues (2006) reported increased
gray matter volume in midbrain from a voxel-based morphometry study of symptomatic adults with TS.
Their midbrain region included approximately STN/VTA. Their finding needs replication and does not
explain our results, but the identification of midbrain is interesting.
Competing Interests: No competing interests were disclosed.
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Kevin J Black, Department of Psychiatry, Washington University in St. Louis, USA
Regarding the change in striatal [11C]raclopride binding from the first to the second scan on the placebo
day (first paragraph of Discussion and Figures 5 and 6), I inadvertently omitted citations to two additional
studies that also support the present results.
Dewey et al, (1992) reported same-day test-retest values for striatal [11C]raclopride binding, using
cerebellum as a reference region, in 6 experiments in 3 baboons. BPND can be calculated from the values
given in Table 1. Mean ± SD striatal BPND was 2.012 ± 0.148 on the first scan of the day and 2.180 ±
0.207 on the second (mean change 8.4%, p=0.026 by paired t test using N=6, following the authors'
analysis; alternatively, collapsing replicate measurements across days to the first- and second-scan
means for each subject, 0.1<p<0.2 by unpaired t test, N=3).
Wang et al. (1999, Table 1) reported test-retest results using a different paradigm in which 7 young healthy
adult human volunteers were studied twice on each of two days, 1-2 weeks apart. The first scan on each
day followed injection of a saline placebo, and the 2nd scan of each day followed injection of
methylphenidate 0.5mg/kg. Comparing the second to the first placebo scans, mean ± SD striatal BP ND
increased from 2.768 ± 0.437 to 2.973 ± 0.442 (mean change 7.8%, p=0.032 by paired t test).
The study by Dewey and colleagues provides additional same-day test-retest data consistent with our
results (compare also refs. 46 and 47 above). The Wang et al. study, which could have been cited with
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results (compare also refs. 46 and 47 above). The Wang et al. study, which could have been cited with
refs. 42-45 above, shows a similar test-retest increase in striatal [11C]raclopride binding over a period of
1-2 weeks, again consistent with a small decrease in synaptic dopamine concentration from the first to
second scan.
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